EUVIMEDEUVIMED entdecken
Crossref

Into the Unknown: Practical Remdesivir Restriction in the Era of Widespread SARS-CoV-2 Seropositivity

Alyssa Christensen iD, Zachary Nelson, Sally Gustafson, Rachel Stoecker iD, Brent Footer iD, Nicole Trower, Laura Grangaard Johnson, Elizabeth B Hirsch, Stefan Collinet-Adler, Maxx Enzmann iD, Ethan Ryberg iD, Sarah Rebecca Peglow

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Alyssa Christensen und 11 weiteren Autor:innen. Beteiligte Einrichtung: HealthPartners and Park Nicollet Health Services, Department of Pharmacy, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Adenosine Monophosphate, COVID-19 Drug Treatment, Alanine. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited data to support routine remdesivir use in the contemporary era of severe acute respiratory syndrome coronavirus 2 with widespread seropositivity.

Methods

A restriction of remdesivir among adult immunocompetent patients was implemented across an 8-hospital health system. A pre–post quasi-experimental design was used to compare patients 12 months pre-intervention (June 2022–May 2023) to 12 months post-intervention (July 2023–June 2024). The primary outcome was 14-day all-cause mortality.

Results

A total of 4774 patients were included in the analysis (3323 pre-intervention, 1451 post-intervention). Significantly fewer patients in the post-intervention group received remdesivir (37.7% pre-intervention versus 4.1% post-intervention; P < .001). When medium-risk covariates were modeled, there was no difference in 14-day all-cause mortality between pre- and post-intervention groups (odds ratio, 1.8; 95% confidence interval: .54–5.8; P = .34). There was no difference in 28-day all-cause mortality, 30-day readmission, or length of hospital stay. Intensive care unit (ICU) admission and mechanical ventilator (MV) use were different between groups. Remdesivir use was associated with a lower risk of ICU admission and MV use pre-intervention and a higher association with these outcomes post-intervention. Similar outcomes were observed with high-risk value covariates.

Conclusions

Restriction of remdesivir use in immunocompetent patients was not associated with an increased risk of mortality. Remdesivir use was associated with an unexpected increased risk of ICU admission and MV use within the post-intervention group, likely explained by the higher-risk patient population that received remdesivir. Prospective studies are needed to definitively determine if highly immunocompetent patients benefit from remdesivir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsAdenosine MonophosphateCOVID-19 Drug TreatmentAlanineSARS-CoV-2COVID-19HumansFemaleMaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

COVID-19antiviralremdesivirrespiratory tract infectionstewardship

Substanzen

remdesivirAntiviral AgentsAdenosine MonophosphateAlanine

Autor:innen und Institutionen

  • HealthPartners and Park Nicollet Health Services, Department of Pharmacy, Minneapolis, Minnesota, USA.
  • HealthPartners Research Institute, Department of Statistical Services, Minneapolis, Minnesota, USA.
  • University of North Carolina Health, Department of Pharmacy, Chapel Hill, North Carolina, USA.
  • HealthPartners Reseach Institute, Department of Reseach Informatics, Minneapolis, Minnesota, USA.
  • University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, USA.
  • HealthPartners and Park Nicollet Health Services, Department of Infectious Diseases, Minneapolis, Minnesota, USA.

ORCID-Profile: Alyssa Christensen, Rachel Stoecker, Brent Footer, Maxx Enzmann, Ethan Ryberg

Zitieren

APA

Christensen, A., Nelson, Z., Gustafson, S., Stoecker, R., Footer, B., Trower, N., Johnson, L. G., Hirsch, E. B., Collinet-Adler, S., Enzmann, M., Ryberg, E., & Peglow, S. R. (2025). Into the Unknown: Practical Remdesivir Restriction in the Era of Widespread SARS-CoV-2 Seropositivity. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf217

Vancouver

Christensen A, Nelson Z, Gustafson S, Stoecker R, Footer B, Trower N, et al. Into the Unknown: Practical Remdesivir Restriction in the Era of Widespread SARS-CoV-2 Seropositivity. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf217

BibTeX
@article{Christensen2025,
  author = {Christensen, Alyssa and Nelson, Zachary and Gustafson, Sally and Stoecker, Rachel and Footer, Brent and Trower, Nicole and Johnson, Laura Grangaard and Hirsch, Elizabeth B and Collinet-Adler, Stefan and Enzmann, Maxx and Ryberg, Ethan and Peglow, Sarah Rebecca},
  title = {Into the Unknown: Practical Remdesivir Restriction in the Era of Widespread SARS-CoV-2 Seropositivity},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf217}
}
Kostenlos starten →